Livforsakringsbolaget Skandia Omsesidigt Cuts Holdings in Vertex Pharmaceuticals Incorporated (VRTX)

Share on StockTwits

Livforsakringsbolaget Skandia Omsesidigt lessened its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 50.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,267 shares of the pharmaceutical company’s stock after selling 2,300 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Vertex Pharmaceuticals were worth $437,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. HPM Partners LLC acquired a new position in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $252,000. Bain Capital Public Equity Management LLC raised its position in shares of Vertex Pharmaceuticals by 168.8% in the second quarter. Bain Capital Public Equity Management LLC now owns 241,408 shares of the pharmaceutical company’s stock valued at $41,030,000 after buying an additional 151,614 shares during the last quarter. Senator Investment Group LP raised its position in shares of Vertex Pharmaceuticals by 80.2% in the second quarter. Senator Investment Group LP now owns 720,000 shares of the pharmaceutical company’s stock valued at $122,371,000 after buying an additional 320,483 shares during the last quarter. Sun Life Financial INC raised its position in shares of Vertex Pharmaceuticals by 266.1% in the second quarter. Sun Life Financial INC now owns 692 shares of the pharmaceutical company’s stock valued at $118,000 after buying an additional 503 shares during the last quarter. Finally, Rampart Investment Management Company LLC grew its holdings in Vertex Pharmaceuticals by 11.0% in the second quarter. Rampart Investment Management Company LLC now owns 7,494 shares of the pharmaceutical company’s stock valued at $1,274,000 after purchasing an additional 741 shares during the period. 93.40% of the stock is owned by institutional investors and hedge funds.

VRTX opened at $169.46 on Thursday. The company has a quick ratio of 3.59, a current ratio of 3.71 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52-week low of $136.50 and a 52-week high of $194.92. The company has a market cap of $43.31 billion, a price-to-earnings ratio of 211.83, a price-to-earnings-growth ratio of 1.72 and a beta of 1.48.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.07. Vertex Pharmaceuticals had a net margin of 22.87% and a return on equity of 22.92%. The company had revenue of $784.54 million during the quarter, compared to the consensus estimate of $782.95 million. During the same period in the previous year, the firm earned $0.53 earnings per share. On average, research analysts predict that Vertex Pharmaceuticals Incorporated will post 2.55 earnings per share for the current fiscal year.

In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 10,083 shares of the business’s stock in a transaction that occurred on Friday, August 3rd. The shares were sold at an average price of $175.29, for a total transaction of $1,767,449.07. Following the completion of the sale, the executive vice president now directly owns 48,877 shares in the company, valued at $8,567,649.33. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Paul M. Silva sold 2,098 shares of the business’s stock in a transaction that occurred on Friday, August 3rd. The stock was sold at an average price of $174.44, for a total transaction of $365,975.12. Following the sale, the senior vice president now owns 17,376 shares of the company’s stock, valued at $3,031,069.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,325 shares of company stock valued at $6,135,340. 0.75% of the stock is owned by insiders.

A number of equities research analysts recently issued reports on VRTX shares. Jefferies Financial Group boosted their target price on shares of Vertex Pharmaceuticals to $210.00 and gave the company a “buy” rating in a report on Monday, July 16th. BMO Capital Markets boosted their target price on shares of Vertex Pharmaceuticals to $204.00 and gave the company an “outperform” rating in a report on Thursday, July 26th. Piper Jaffray Companies boosted their target price on shares of Vertex Pharmaceuticals to $230.00 and gave the company an “overweight” rating in a report on Thursday, July 26th. Oppenheimer boosted their target price on shares of Vertex Pharmaceuticals from $180.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, July 26th. Finally, Morgan Stanley boosted their target price on shares of Vertex Pharmaceuticals from $207.00 to $211.00 and gave the company an “overweight” rating in a report on Thursday, July 26th. Three equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $202.14.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Featured Story: Understanding Analyst Recommendations

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply